Patent Number | Title | Applicant | Opposition Date |
---|---|---|---|
EP4019041 | Toxicity Management For Anti-Tumor Activity Of Cars | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | Sep 28, 2023 |
EP3119423 | Treatment Of Cancer Using Chimeric Antigen Receptor | NOVARTIS AG | Sep 14, 2023 |
EP3253865 | Methods For Enhancing Efficacy Of Therapeutic Immune Cells | NATIONAL UNIVERSITY OF SINGAPORE | Mar 21, 2023 |
EP3261651 | Chimeric Antigen Receptors (Cars) Targeting Hematologic Malignancies, Compositions And Methods Of Use Thereof | CHEN, KEVIN | Feb 3, 2023 |
EP3827845 | Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses | JANSSEN BIOTECH, INC. | Dec 29, 2022 |
EP3166976 | Anti-Pd-L1 Combinations For Treating Tumors | BIRDIE BIOPHARMACEUTICALS INC. | Nov 23, 2022 |
EP3248986 | Immunoglobulin Variable Domains | ABLYNX NV | Oct 25, 2022 |
EP3590949 | Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof | MODERNATX, INC. | Sep 27, 2022 |
EP3433276 | Early Intervention Methods To Prevent Or Ameliorate Toxicity | SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) | Sep 22, 2022 |
EP3733847 | Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use Thereof | TOOLGEN INCORPORATED | Sep 7, 2022 |
Feel free to send us a message here and we will get back to you